公开(公告)号：US20170217897A1

公开(公告)日：2017-08-03

申请号：US15500870

申请日：2015-08-03

Applicant: Zhigan JIANG ,  Jianhua XIA ,  Haiying HE ,  NOVARTIS AG

Inventor： Javier de Vicente FIDALGO ,  Haiying HE ,  Cheng HU ,  Zhigan JIANG ,  Xiaolin LI ,  Peichao LU ,  Wosenu MERGO ,  Daniel MUTNICK ,  Folkert RECK ,  Alexey RIVKIN ,  Colin Keith SKEPPER ,  Xiaojing Michael WANG ,  Jianhua XIA ,  Yongjin XU

IPC: C07D215/38 ,  A61K31/4709 ,  A61K31/496 ,  C07D401/14 ,  C07D413/14 ,  C07D419/14 ,  C07D405/14 ,  C07D471/04 ,  C07D498/10 ,  A61K31/5377 ,  A61K31/5386 ,  C07D487/10 ,  C07D471/10 ,  A61K45/06 ,  C07D401/04

CPC classification number: C07D215/38 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/5386 ,  A61K45/06 ,  C07D215/22 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D419/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/10 ,  C07D498/10 ,  Y02A50/406 ,  Y02A50/47 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/481

Abstract: This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof, that inhibit bacterial gyrase. The compounds are useful as inhibitors of bacterial gyrase activity and bacterial infections, and have the structure of Formula (I) as further described herein. The invention further provides pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds and compositions to treat bacterial infections.

公开(公告)号：US20190175606A1

公开(公告)日：2019-06-13

申请号：US16274165

申请日：2019-02-12

Applicant: NOVARTIS AG

Inventor： Robert John AVERSA ,  Paul Andrew BARSANTI ,  Matthew T. BURGER ,  Michael Patrick DILLON ,  Alan DIPESA ,  Cheng HU ,  Yan LOU ,  Gisele A. NISHIGUCHI ,  Yue PAN ,  Valery Rostislavovich POLYAKOV ,  Savithri RAMURTHY ,  Alice C. RICO ,  Lina Quattrocchio SETTI ,  Aaron SMITH ,  Sharadha SUBRAMANIAN ,  Benjamin R. TAFT ,  Huw Roland TANNER ,  Lifeng WAN ,  Naeem YUSUFF

IPC: A61K31/5377 ,  C07D493/10 ,  C07D403/12 ,  C07D413/14 ,  C07D413/12 ,  C07D403/04 ,  C07D401/12 ,  C07D277/42 ,  C07D239/48 ,  C07D239/47 ,  C07D239/42 ,  C07D237/20 ,  C07D213/74 ,  A61K45/06 ,  A61K31/541 ,  C07D413/04 ,  C07D491/08 ,  C07B59/00 ,  C07D417/12 ,  C07D237/24 ,  C07D491/04 ,  A61K31/444 ,  A61K31/501 ,  C07D513/04 ,  C07D491/048 ,  A61K31/5375 ,  C07D213/81 ,  C07D213/82 ,  C07D213/84 ,  C07D237/22 ,  C07D409/14 ,  C07D498/08 ,  C07D495/04 ,  C07D493/04 ,  C07D491/107 ,  C07D263/58 ,  C07D487/04 ,  C07D471/04 ,  C07D241/20 ,  C07D405/12 ,  C07D405/04 ,  C07D401/04 ,  C07D233/88 ,  C07D213/75 ,  C07D405/14 ,  C07D401/14

Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

公开(公告)号：US20170260207A1

公开(公告)日：2017-09-14

申请号：US15601423

申请日：2017-05-22

Applicant: NOVARTIS AG

Inventor： Robert John AVERSA ,  Paul Andrew BARSANTI ,  Matthew T. BURGER ,  Michael Patrick DILLON ,  Alan DIPESA ,  Cheng HU ,  Yan LOU ,  Gisele A. NISHIGUCHI ,  Yue PAN ,  Valery Rostislavovich POLYAKOV ,  Savithri RAMURTHY ,  Alice C. RICO ,  Lina Quattrocchio SETTI ,  Aaron SMITH ,  Sharadha SUBRAMANIAN ,  Benjamin R. TAFT ,  Huw Roland TANNER ,  Lifeng WAN ,  Naeem YUSUFF

IPC: C07D513/04 ,  A61K31/5377 ,  C07D213/74 ,  C07D237/22 ,  C07D213/84 ,  C07D213/81 ,  C07D213/75 ,  C07D401/14 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D491/08 ,  A61K31/444 ,  C07D241/20 ,  C07D401/04 ,  C07D237/24 ,  C07D237/20 ,  A61K31/501 ,  C07D239/48 ,  C07D403/04 ,  C07D487/04 ,  C07D471/04 ,  C07D263/58 ,  C07D495/04 ,  C07D491/04 ,  C07D409/14 ,  C07D413/04 ,  C07B59/00 ,  C07D401/12

CPC classification number: A61K31/5377 ,  A61K31/444 ,  A61K31/501 ,  A61K31/5375 ,  A61K31/541 ,  A61K45/06 ,  C07B59/002 ,  C07B2200/05 ,  C07D213/74 ,  C07D213/75 ,  C07D213/81 ,  C07D213/82 ,  C07D213/84 ,  C07D233/88 ,  C07D237/20 ,  C07D237/22 ,  C07D237/24 ,  C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D241/20 ,  C07D263/58 ,  C07D277/42 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/048 ,  C07D491/08 ,  C07D491/107 ,  C07D493/04 ,  C07D493/10 ,  C07D495/04 ,  C07D498/08 ,  C07D513/04

Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.